ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics, Inc.

Baxalta Pharmaceutical Company is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

Baxalta Pharmaceutical Company

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. It comprises CSL Behring, CSL Seqirus, and CSL Vifor, providing diverse offerings to ensure patients and people everywhere get the treatments they need.

Grifols is a global healthcare company that specializes in developing plasma-derived medicines and innovative biopharmaceutical solutions to improve the health and well-being of people around the world. With a history dating back to 1909, the company has a strong focus on treating a broad range of therapeutic areas, including neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Grifols is also a pioneer in the plasma industry and has a significant global presence, providing its healthcare products and solutions in more than 110 countries.

Grifols, S.A.

ADMA Biologics, Inc. specializes in developing and manufacturing plasma-derived products for patients with immune deficiencies, utilizing proprietary immunotechnology.

Metric
Company Name	ADMA Biologics, Inc.	Baxalta Pharmaceutical Company	CSL	Grifols, S.A.
Symbol	ADMA
MSH ID	COM:ADMABIOLOGICS	COM:BAXALTAPHARMACEUTICAL	COM:CSL	COM:GRIFOLS
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology and Pharmaceuticals	Healthcare & Health Services
Country	US	US	AU	ES
Stage
Employee Count	624		20.94K	10.51K
Website	admabiologics.com	baxaltapharmaceutical.com	csl.com	grifols.com
LinkedIn			csl	grifols
Founders

Metric
Market Cap	2.78B	5.87B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	258.21M
Revenue (LTM)
Revenue (NTM)
Gross Profit	88.22M
EBITDA	29.96M
Operating Income	21.63M
Net Income	-28.24M
EPS	-0.13
Diluted EPS	-0.13
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.46
Operating Profit Margin	0.25
EBITDA Margin	0.12
Net Profit Margin	0.11
Return on Equity	0.22
Return on Assets	0.09
Return on Capital Employed	0.25

COM:ADMABIOLOGICS

ADMA Biologics, Inc.

Last Close

21.30

22/11 21:00

Market Cap

2.78B

Beta: -

Volume Today

2.10M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-27.46
P/B Ratio	7.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	14.73
EV Multiple	57.98

Metric
Days Sales Outstanding	48.79
Days Payables Outstanding	24.41
Days Inventory Outstanding	377.54
Operating Cycle	441.50
Cash Conversion Cycle	405.00
Asset Turnover	0.88

Metric
Operating Cash Flow	8.80M
Free Cash Flow	3.82M
Cash Flow to Debt	0.55
Operating Cash Flow/Sales	0.22
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	51.35M
Accounts Receivable	-11.92M
Inventory	172.91M
Goodwill	3.53M
Debt to Capitalization	0.49
Debt to Assets	0.44
Current Ratio	6.54
Quick Ratio	2.80

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02
R&D to Revenue	0.02
SG&A to Revenue